GLP-1s and Knee Osteoarthritis: New Trial Data for Pain and Function

Quick Answer

New trial data suggests GLP-1 receptor agonists may improve knee osteoarthritis pain and physical function beyond the effect of weight loss alone. The STEP OA trial found semaglutide significantly reduced WOMAC pain scores and improved function in people with moderate knee OA and obesity. Eli Lilly's TRIUMPH-4 trial confirmed the OA benefit extends to retatrutide, their next-generation triple-agonist. Anti-inflammatory and possible direct cartilage-protective effects may explain the added benefit beyond weight loss. If you have knee OA, GLP-1-mediated weight loss is one of the most evidence-backed strategies to reduce joint stress — and the emerging data hints the drug may do more than just lighten the load.

Key Points

• The STEP OA phase 3 trial found semaglutide reduced knee OA pain by ~42% on the WOMAC pain scale vs. ~28% for placebo, on top of weight loss
• Eli Lilly's TRIUMPH-4 trial confirmed retatrutide (a triple-agonist) also improves knee OA outcomes, with 22.3-28.7% weight loss in OA patients
• Weight loss from GLP-1s reduces mechanical stress on knees: every 1 lb lost = 4 lb less knee joint pressure
• GLP-1 receptors exist in joint tissues; the drugs may have direct anti-inflammatory and cartilage-protective effects
• Functional improvements (walking, stair climbing) were significantly greater with semaglutide vs. placebo
• People with knee OA and BMI ≥30 may benefit most from GLP-1 therapy for joint outcomes
• GLP-1s are not a replacement for standard OA care (PT, NSAIDs, injections) but may complement it

Why This Matters

Knee osteoarthritis is one of the most common causes of chronic pain and disability worldwide, affecting roughly 250 million people. Obesity is the single strongest modifiable risk factor — not just because extra weight loads the joint, but because fat tissue drives systemic inflammation that accelerates cartilage breakdown.

For years, the advice has been simple: lose weight, and your knees will feel better. That remains true. But new clinical trial data adds a wrinkle: GLP-1 medications may improve knee OA outcomes beyond what weight loss alone can explain.

This is a developing story, not a settled conclusion. Here's what we know so far.

The STEP OA Trial: Semaglutide and Knee OA

The most direct evidence comes from the STEP OA trial (Semaglutide Treatment Effect in People with Obesity and Osteoarthritis), a phase 3 randomized controlled trial sponsored by Novo Nordisk. Results were presented at EASD 2025 and reinforced with additional analysis at ECO 2026 (European Congress on Obesity).

Trial Design

• Population: Adults with BMI ≥30 and moderate knee osteoarthritis (Kellgren-Lawrence grade 2-3)
• Intervention: Semaglutide 2.4 mg weekly (the Wegovy dose) vs. placebo, both with lifestyle counseling
• Duration: 68 weeks
• Primary endpoint: Change in WOMAC pain score (a validated OA pain and function scale)
• Key secondary endpoints: Change in WOMAC physical function score, body weight, and OA structural biomarkers

Results

The semaglutide group reported meaningfully less pain and better function. The placebo group also improved (likely from lifestyle counseling and the placebo effect), but the difference was statistically and clinically significant.

The ECO 2026 presentation provided longer-term follow-up analysis, reinforcing the durability of these findings and showing that pain and function improvements were maintained with continued treatment.

The Key Question: Weight Loss or Something More?

Here's where it gets interesting. The researchers analyzed whether the pain improvement could be fully explained by the amount of weight lost. Their finding: weight loss accounted for a large portion of the benefit, but semaglutide's effect on OA pain was greater than what weight loss alone predicted.

This suggests one of two things (or both):

1. Anti-inflammatory effects. GLP-1 receptor agonists reduce systemic inflammation markers (CRP, IL-6, TNF-alpha). Since OA is increasingly understood as an inflammatory disease — not just "wear and tear" — reducing inflammation at the joint level could provide additional pain relief beyond simply unloading the knee.

2. Direct joint tissue effects. GLP-1 receptors have been identified on chondrocytes (cartilage cells) and synovial tissue. Preclinical data suggests GLP-1 receptor activation may protect cartilage from inflammatory degradation. If this translates to humans, semaglutide may be doing something directly at the joint, not just systemically.

The trial was not designed to definitively separate these mechanisms. But the signal is there, and it's being taken seriously by the rheumatology community.

The TRIUMPH-4 Trial: Retatrutide and Knee OA

The OA benefit isn't limited to semaglutide. Eli Lilly's TRIUMPH-4 trial tested retatrutide — a next-generation triple-agonist (GLP-1 + GIP + glucagon) — specifically in adults with obesity and knee osteoarthritis. Results were reported in December 2025.

Results

The weight loss was dramatically larger than in the STEP OA trial — up to 28.7% with retatrutide vs. 13.5% with semaglutide. That translates to substantially more mechanical unloading of the knee joint.

What TRIUMPH-4 Adds to the Picture

The TRIUMPH-4 trial is significant for two reasons:

1. Class effect confirmed. Retatrutide works on GLP-1, GIP, and glucagon receptors — a different mechanism profile than semaglutide (GLP-1 only). The fact that both drugs improve knee OA outcomes suggests the benefit is a class effect of GLP-1 receptor agonists, not something unique to semaglutide.

2. Dose-response signal. The 28.7% weight loss with retatrutide 12 mg is nearly double what semaglutide achieved. If more weight loss = more OA improvement (which the data strongly supports), next-generation GLP-1 drugs could produce even greater joint benefits.

Retatrutide is not yet FDA-approved and is not available by prescription. See our retatrutide guide for the full picture on this investigational drug, including all three Phase 3 trial results and the approval timeline.

How Weight Loss Helps Knee OA: The Mechanics

Before GLP-1s entered the picture, the weight-loss-OA connection was already well-established:

• 1 lb lost = 4 lb less peak knee load. During walking, your knee absorbs roughly 3-4x your body weight with each step. Lose 20 lbs and you've removed 60-80 lbs of force per step.
• Inflammation reduction. Adipose (fat) tissue is metabolically active — it secretes pro-inflammatory cytokines (adipokines) that accelerate cartilage breakdown. Less fat = less inflammatory signaling to joints.
• Improved biomechanics. Weight loss changes gait, posture, and alignment. Even modest reductions can shift load from the worn part of the joint to healthier cartilage areas.

Research consistently shows that a 5-10% reduction in body weight produces meaningful pain relief in knee OA. A 10% loss is associated with roughly a 50% reduction in knee OA pain. GLP-1s are one of the most effective tools available for achieving and sustaining that level of weight loss.

GLP-1s and Inflammation: Beyond the Scale

The anti-inflammatory properties of GLP-1 receptor agonists are increasingly well-documented:

• Reduced CRP. Semaglutide and tirzepatide both reduce high-sensitivity C-reactive protein (hs-CRP), a marker of systemic inflammation.
• Lower IL-6 and TNF-alpha. These cytokines are central drivers of OA inflammation. GLP-1s have been shown to reduce circulating levels of both.
• Synovial inflammation. Small studies suggest GLP-1 receptor agonists may reduce synovitis (inflammation of the joint lining), which is a major source of OA pain independent of cartilage damage.

This anti-inflammatory profile helps explain why GLP-1s appear to outperform weight loss from diet or bariatric surgery in some inflammatory outcomes. The drug isn't just helping you lose weight — it's actively modulating the immune signaling that drives joint damage.

If you're also experiencing GLP-1-related joint pain as a side effect, that's a different mechanism (typically related to dehydration or biomechanical adaptation during rapid weight loss). The longer-term trend for most people is less joint pain, not more.

Who Might Benefit Most

Based on current evidence, the people most likely to see OA-specific benefits from GLP-1s are:

• BMI ≥30 with moderate knee OA. This is the STEP OA population, and where the data is strongest.
• BMI 27-30 with OA and a weight-related comorbidity (type 2 diabetes, hypertension, sleep apnea). GLP-1 therapy may be indicated for weight management regardless, and the OA benefit is a meaningful secondary effect.
• People who haven't responded adequately to standard OA treatments (physical therapy, NSAIDs, injections) and who also meet criteria for GLP-1 therapy.
• People with inflammatory OA phenotypes. OA is increasingly classified into subtypes. People with prominent synovitis and systemic inflammation markers may benefit most from the anti-inflammatory effects of GLP-1s, though this hasn't been tested in a dedicated trial.

People who are at a healthy weight but have OA from injury or alignment issues may still benefit from the anti-inflammatory effects, but there's no trial data in this population, and GLP-1s are not typically prescribed for people without obesity or a weight-related condition.

What This Does NOT Mean

Important caveats:

• GLP-1s are not FDA-approved for osteoarthritis. The STEP OA and TRIUMPH-4 trials are promising but do not constitute an approved indication for any GLP-1 drug.
• GLP-1s do not regrow cartilage. There is no evidence that semaglutide or any GLP-1 reverses structural joint damage. The benefit appears to be pain and function improvement, possibly driven by reduced inflammation and loading.
• This is not a replacement for standard OA care. Physical therapy, appropriate exercise, weight management, NSAIDs, and intra-articular injections all have a role. GLP-1 therapy should complement, not replace, these interventions.
• Retatrutide is not available yet. Despite strong trial results, retatrutide has not been submitted to the FDA. It cannot be prescribed. The earliest possible approval is likely 2027.
• The long-term joint outcomes are unknown. The STEP OA trial ran for 68 weeks; TRIUMPH-4 ran for 72 weeks. We don't yet know whether the OA benefits persist, plateau, or change over multi-year treatment.

Practical Takeaways: What to Do Now

If You Have Knee OA and Are Considering a GLP-1

1. Talk to your doctor about whether you qualify. GLP-1s are indicated for obesity (BMI ≥30) or overweight (BMI ≥27) with a comorbidity. If you meet these criteria, your knee OA is a supporting reason — not the sole indication — but it's a legitimate one.

2. Set realistic expectations. GLP-1 therapy is likely to help your knee pain through weight loss and possibly additional anti-inflammatory effects. It's not a cure for OA, and it won't replace the joint.

3. Combine with exercise. The STEP OA trial included lifestyle counseling. Weight loss alone is helpful; weight loss + exercise is significantly better for OA outcomes. See our GLP-1 exercise guide for a program that's gentle on joints.

4. Don't neglect bone health. Rapid weight loss can reduce bone mineral density. Calcium, vitamin D, and resistance training are essential countermeasures — especially important when you have OA, since bone health and joint health are intertwined.

If You're Already on a GLP-1 and Have Knee OA

1. Track your symptoms. Use a simple pain scale (0-10) at baseline and monthly. Many people notice gradual improvement as weight loss progresses.

2. Stay active. Movement lubricates joints. Low-impact exercise (walking, swimming, cycling, yoga) is ideal.

3. Stay hydrated. Dehydrated joints are stiff joints. GLP-1s can reduce thirst perception — be intentional about fluid intake.

4. Continue your existing OA treatments. Don't stop physical therapy, NSAIDs, or injections just because you're losing weight. The combination is likely better than either alone.

5. Watch for joint pain side effects. Some people experience temporary joint discomfort during the first weeks of GLP-1 therapy as the body adjusts. This is different from OA pain and typically resolves.

What's Coming

The STEP OA and TRIUMPH-4 trials are the first major RCTs to test GLP-1–class drugs in OA populations. Several developments are on the horizon:

• Longer follow-up data from STEP OA is expected, including additional analysis from ECO 2026 presentations, which will clarify whether the benefits are sustained with continued treatment.
• Tirzepatide (Mounjaro/Zepbound) OA data. No dedicated OA trial for tirzepatide has been published yet, but the drug's stronger weight loss and anti-inflammatory effects make it a logical candidate for OA benefit.
• Retatrutide FDA filing. If the remaining Phase 3 trials are positive, Eli Lilly could file retatrutide for FDA review in late 2026 or early 2027. Approval would make a drug with specific knee OA trial data available for the first time. See our retatrutide guide for timeline details.
• Structural outcome trials. Future studies may use MRI to assess whether GLP-1s slow cartilage loss or reduce synovitis over time — not just improve pain scores.
• Combination therapy studies. Trials combining GLP-1s with physical therapy, anti-inflammatory diets, or other OA drugs could help define the optimal treatment stack.

The Bottom Line

The data on GLP-1s and knee osteoarthritis is early but genuinely promising. Semaglutide reduced OA pain and improved function in the STEP OA trial, and the benefit appears to go beyond what weight loss alone explains. Retatrutide's TRIUMPH-4 trial confirms this is a class effect, not a one-drug anomaly. Anti-inflammatory and possible direct joint-tissue effects may be at play.

If you have knee OA and also meet criteria for GLP-1 therapy, the joint benefits are a real — and now evidence-supported — reason to consider it. But GLP-1s are not an OA drug. They're a weight-loss and metabolic medication that happens to help joints, and they should be part of a broader OA management plan.

Your action items:

1. If you have knee OA + obesity, talk to your doctor about GLP-1 therapy
2. Combine weight loss with low-impact exercise for the best joint outcomes
3. Stay hydrated, eat anti-inflammatory foods, and protect your bone health
4. Track your symptoms so you can tell whether the medication is helping
5. Don't stop existing OA treatments — add to them

Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before starting or changing any medication or treatment plan. Individual results vary, and GLP-1 medications are not FDA-approved for osteoarthritis treatment. Retatrutide is an investigational drug that is not yet approved by the FDA.

Found this helpful? Share it with someone managing knee OA who might benefit from knowing about this emerging research.

Related Reading

• GLP-1s and Joint Pain: Why Your Joints May Hurt (and What Helps)
• GLP-1 and Bone Health: Does Ozempic Cause Bone Loss?
• Exercise on GLP-1: A Simple Guide
• Retatrutide Guide: TRIUMPH-1 Phase 3 Results and What Comes Next
• GLP-1 Weight Loss After 1 Year: Real Results and What to Expect
• GLP-1s and Gout: Why Rapid Weight Loss Can Trigger Flares